A composite index for predicting improvement of mitral regurgitation in patients with multivalvular heart disease after transcatheter aortic valve replacement

经导管主动脉瓣置换术后多瓣膜心脏病患者二尖瓣反流改善的预测综合指标

阅读:1

Abstract

BACKGROUND: Transcatheter aortic valve replacement (TAVR) has become a standard treatment for severe aortic stenosis (AS). Concomitant mitral regurgitation (MR) is observed in approximately 19%-29% of these patients. Although MR frequently improves after TAVR, persistent MR is associated with worse clinical outcomes, highlighting the need for reliable predictors of MR persistence. METHODS: We conducted a single-center, retrospective study that included 53 patients with severe AS and moderate-to-severe MR who underwent TAVR between 2017 and 2024. The primary outcome was MR improvement, defined as a reduction of at least one grade at the 1-year follow-up. To identify independent predictors, we performed multivariable logistic regression analysis. RESULTS: At 1-year follow-up, MR improvement was observed in 67.9% of patients. Multivariable analysis identified persistent atrial fibrillation [odds ratio (OR): 0.099, 95% CI: 0.017-0.575; P = 0.01] and eccentric MR (OR: 0.066, 95% CI: 0.012-0.370; P = 0.002) as independent negative predictors of improvement. Conversely, greater interventricular septal thickness (OR: 1.825, 95% CI: 1.075-3.099; P = 0.026) was a positive predictor. A composite predictive index integrating these three variables demonstrated excellent discriminative ability, with an area under the receiver operating characteristic curve of 0.909. CONCLUSION: This study identifies persistent atrial fibrillation, eccentric MR, and interventricular septal thickness as key independent predictors of MR improvement after TAVR. The derived composite index, with its outstanding predictive performance, provides a novel tool to aid in patient selection and prognostic assessment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。